SRGN and Miyoshi myopathy: In addition, secreted serglycin was found to influence the bone mineralization process through inhibition of the crystal growth rate of hydroxyapatite, thus providing another possible explanation for impaired bone formation and loss of bone mass commonly seen in MM patients (16).